ClinicalTrials.gg
TerminatedNCT01869738MASTER-IIUpdated Sep 2, 2015

MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction

An interventional study of MGuard Prime and (BMS/DES) in ST Elevation Myocardial Infarction, sponsored by InspireMD. Terminated at 56 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-02.

Sponsored by InspireMD · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
low enrollment rate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 83 studies in ST Elevation Myocardial Infarction with a site in United States — 6 open to participants now, 11 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · United States.

Enrollment
19th of 56
310 · median 101
Started
2013
with 5 others
No phase
23 of 83
3 open now
Registered
25th of 83
by date

Among the 83 studies in ST Elevation Myocardial Infarction with a site in United States, this one is the 19th largest by enrollment of the 56 interventional ones that give a count, is one of 6 that started in 2013, is one of 23 with no phase, and was the 25th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

6 of the 83 studies in ST Elevation Myocardial Infarction with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in ST Elevation Myocardial Infarction with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of the MGuard™ Prime stent in the treatment of blocked arteries in coronary arteries in patients undergoing a stenting procedure due to having a heart attack. The MGuard Prime stent wil be compared to other FDA approved bare-metal (BMS) or drug-eluting (DES) coronary stents. The hypotheses are that (1) the MGuard Prime stent will achieve a higher rate of complete ST-segment resolution as seen on the post-procedure ECG as compared to the comparator stent, and will have a similar effect on the rate of all-cause death or recurrent target vessel myocardial infarction at 365 days post-procedure.

03

Conditions studied

  • ST Elevation Myocardial Infarction

Keywords

  • heart attack
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is more than 18 years of age
  • Subject is experiencing clinical symptoms consistent with acute myocardial infarction (AMI) of more than 30 minutes and less than 12 hours in duration.
  • ST elevation more than 2 mm per lead in more than 2 contiguous leads is present in one prior to consent.
  • Subject agrees to all required follow-up procedures and visits.
  • Subject or legal representative provides written, .
  • The target lesion is a de novo lesion in a native coronary artery.
  • Based on coronary anatomy, PCI is indicated for the culprit lesion with anticipated use of stenting.
  • The reference vessel diameter (RVD) of the infarct lesion is 2.75 to 4.0 mm by visual assessment, assessed either at baseline (if direct stenting is planned), or after pre-dilatation or thrombus aspiration (if direct stenting is not planned).
  • The entire lesion length requiring treatment is less than 24 mm (able to be covered by a single study stent), assessed either at baseline (if direct stenting is planned), or after pre-dilatation or thrombus aspiration (if direct stenting is not planned)
  • TIMI flow of 2/3 is present prior to randomization (in case of baseline TIMI flow 0/1, blood flow must be restored).

Exclusion criteria

Exclusion Criteria:

  • Left bundle branch block (LBBB), paced rhythm, or other abnormality interfering with assessment of ST-segment.
  • Currently enrolled in another device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints.
  • A previous coronary interventional procedure of any kind within 30 days prior to the procedure.
  • Female patients of .
  • Subject undergoing cardiopulmonary resuscitation (patients in whom cardiopulmonary resuscitation was successfully performed and in whom normal mental status was achieved, may be enrolled).
  • Cardiogenic shock (SBP less than 80 mmHg for more than other hemodynamic support device for hypotension).
  • The subject requires a staged procedure of the target vessel (including branches) within 12 months or of any non-target vessel within 7 days post-procedure.
  • The target lesion requires treatment with a device other than PTCA prior to stent placement (such as, but not limited to excimer laser, rotational atherectomy, etc.). Manual thrombus aspiration may be used per operator discretion, but rheolytic thrombectomy is only permitted for procedural complications after randomization.
  • Prior administration of thrombolytic therapy for the current admission
  • Co-morbid condition(s) that could limit the subject's ability to participate in the trial or to comply with follow-up requirements, or impact the scientific integrity of the trial.
  • Concurrent medical condition with a of less than 12 months.
  • History of cerebrovascular accident or within the last 6 months, or any permanent neurologic deficit
  • Prior intracranial bleed at any time, or known intracranial pathology (e.g. tumor, arteriovenous malformation, or aneurysm).
  • Active or recent site of major bleeding within 6 months.
  • History of bleeding diathesis or coagulopathy or inability to accept blood transfusions.
  • Known or to either i) aspirin, or heparin and bivalirudin; or ii) clopidogrel , ticlopidine, prasugrel and ticagrelor; or iii) cobalt or nickel; or iv) contrast media, which cannot be adequately pre-medicated (prior anaphylaxis, however, is an absolute contraindication to enrollment).
  • Known serum creatinine level more than 2.5 mg/dl, less than 10 g/dL or count less than 150,000 for the present admission or within 7 days prior to index procedure, if available.
  • Surgery planned or any other reason necessitating discontinuation of dual anti-platelet therapy (aspirin and an ADP antagonist) within 12 months
  • Aortic dissection or mechanical complication of STEMI
  • Unprotected left main stenosis more than 50%.
  • Multi-vessel intervention required during the index procedure.
  • Excessive tortuosity, calcification or diffuse distal disease
  • A non-infarct lesion with stenosis more than 50% is present in the target vessel
  • Target lesion is a bifurcation with a side branch more than 2.0 mm in diameter.
  • Target lesion at the site of or within a vessel with a previously implanted stent
  • Target lesion is within a bypass graft conduit, or can only be reached by passing the study stent through a bypass graft conduit
  • In the Investigator's opinion the lesion/vessel is unsuitable for treatment with the study stent for any reason.
  • The lesion requires use of atherectomy, thrombectomy (not including manual thrombus aspiration catheters), laser devices, or proximal or distal embolic protection devices prior to randomization.
  • Aortic dissection or mechanical complication of STEMI
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
310 participants (actual)

Study arms

  • Experimental
    MGuard Prime

    MGuard Prime stent

    Device: MGuard Prime

  • Active comparator
    Control

    (BMS/DES) Includes FDA approved bare metal or drug eluting stents, including ENDEAVOR, TAXUS Liberte, XIENCE Prime, PROMUS Element, ION, RESOLUTE, Driver, Vision, VeriFlex and Integrity.

    Device: (BMS/DES)

Interventions

  • DeviceMGuard Prime
  • Device(BMS/DES)
06

What researchers measure

Primary outcomes

  1. rate of complete ST-segment resolution within 60-90 minutes

    Time frame: 60-90 minutes post-procedure

  2. The primary safety endpoint is a composite of all-cause death or recurrent target vessel myocardial infarction (TV re-MI) at 365 days post-procedure, powered to demonstrate non-inferiority of the MGuard™ Prime Stent compared to the control arm.

    Time frame: 365 days post-procedure

Secondary outcomes

  1. Infarct size assessed by cardiac magnetic resonance imaging (MRI)

    Time frame: 5 days post-procedure

  2. In-stent late lumen loss (LLL)

    Time frame: 13 months post-procedure

07

Study locations

56 sites
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Pepin Heart Hospital
    Tampa, Florida 33613, United States
  • Alexian Brothers Medical Center
    Elk Grove Village, Illinois 60007, United States
  • St. Vincent Medical Group
    Indianapolis, Indiana 46290, United States
  • MedStar Union Memorial Hospital
    Baltimore, Maryland 21218, United States
  • MedStar Southern Maryland Hospital Center
    Clinton, Maryland 20735, United States
  • Sparrow Clinical Research Institute
    Lansing, Michigan 48910, United States
  • Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • Cardiology Associates of North Mississippi
    Oxford, Mississippi 38655, United States
  • Valley Hospital
    Ridgewood, New Jersey 07450, United States
  • Columbia University Medical Center
    New York, New York 10027, United States
  • Asheville Cardiology Associates
    Asheville, North Carolina 28803, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Elyria Memorial Hospital
    Oberlin, Ohio 44074, United States
  • Northwest Ohio Cardiology
    Toledo, Ohio 43615, United States
  • Holy Spirit Hospital
    Camp Hill, Pennsylvania 17011, United States
  • Geisinger Clinic Cardiology
    Danville, Pennsylvania 17822, United States
  • Miriam Hospital
    Providence, Rhode Island 02906, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22903, United States
  • Winchester Medical Center
    Winchester, Virginia 22604, United States
  • ZNA Antwerpem
    Antwerp, Belgium
  • University hospital
    Hradec Kralove, Czech Republic
  • Na Homolce Hospital
    Prague, Czech Republic
  • North-Estonia Regional Hospital
    Tallinn, 13419, Estonia
  • Helsinki University Hospital
    Helsinki, Finland
  • Hopital Henri Mondor
    Créteil, France
  • Hopital Louis Pradel
    Lyon, France
  • Institut Jacques Cartier
    Massy, France
  • Hôpitaux GHI Le Raincy - Montfermeil
    Montfermeil, France
  • Hôptal Européen Georges Pompidou
    Paris, France
  • Charité Universitätsklinikum Berlin Campus Benjamin Franklin
    Berlin, 10117, Germany
  • Charité Universitätsklinikum Berlin Campus Virchow
    Berlin, 10117, Germany
  • Stadtische Kliniken München
    Munich, 81925, Germany
  • Krankenhaus der Barmherzigen Brüder
    Trier, 54292, Germany
  • Universitat Ulm
    Ulm, 89081, Germany
  • Rabin Medical Center
    Petach Tikva, 49100, Israel
  • Onze Lieve Vrouwe Gasthuis
    Amsterdam, AC 1091, Netherlands
  • VU University Medical Center
    Amsterdam, 1081, Netherlands
  • Academic Medical Center
    Amsterdam, Netherlands
  • Albert Schweitzerziekenhuis
    Dordrecht, 3318, Netherlands
  • Malopolskie Centrum Sercowo-Naczyniowe
    Chrzanow, Poland
  • Polsko-Amerykańskie Kliniki Serca
    Dąbrowa Górnicza, Poland
  • Górnośląskie Centrum Medyczne
    Katowice, 40-635, Poland
  • Krakowskie Centrum Kardiologii Inwazyjnej
    Krakow, 30-693, Poland
  • Szpital Uniwersyteckiw Krakowie
    Krakow, 31-501, Poland
  • John Paul II Hospital
    Krakow, Poland
  • Klinika Kardiologii i Angiologii Interwencyjnej
    Warsaw, 04 - 628, Poland
  • Katedra i Klinika Kardiologii Uniwersytetu Medycznego w Łodzi
    Łódź, Poland
  • Hospital Clinic, University of Barcelona
    Barcelona, 08036, Spain
  • Bellvitge University Hospital
    Barcelona, 08907, Spain
  • Hospital Universitario Madrid Montepríncipe
    Madrid, 28660, Spain
  • Bristol Heart Institute
    Bristol, United Kingdom
  • University Hospital of Wales
    Cardiff, United Kingdom
  • Golden Jubilee National Hospital
    Glasgow, United Kingdom
  • Leeds General Infirmary
    Leeds, United Kingdom
  • University Hospitals Southampton NHS Foundation Trust
    Southampton, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2013
First posted
Jun 5, 2013
Start
Jun 2013
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Last update
Sep 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01869738
Lead sponsor
InspireMD
Responsible party
Sponsor
First posted
Jun 5, 2013
Start date
Jun 2013
Primary completion
Aug 2015
Completion
Aug 2015
Last update
Sep 2, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion